BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral dise...
Clinically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1...
Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the expanded commercial availability of the NavDx ...
Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by found...
Andreessen Horowitz (a16z) Bio + Health announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health...
Atropos Health, a pioneer in translating real-world clinical data into real-world evidence (RWE) for decision-making, today announced i...
Bayer announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for KERENDIA® (finerenone...
-Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma announced a strategic partnership to accelerate the development and commercializatio...
Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, a...
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announce...
-Revvity, Inc. announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemilu...
The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and speci...
Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administrat...
Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, anno...
© 2025 Biopharma Boardroom. All Rights Reserved.
